Although the relationship of CYP2C19 polymorphism to citalopram disposition has been
studied in healthy subject, this relationship in combination with dynamic effects (clinical …

The study was designed to define the contribution of cytochrome P450 2C19 (CYP2C19)
and cytochrome P450 3A4 (CYP3A4) to citalopram N-demethylation and to evaluate the …

Background Citalopram and escitalopram, selective serotonin reuptake inhibitors, are
primarily metabolized by cytochrome P450 (CYP) 2C19, which is a highly polymorphic …

We investigate the impact of sex and genotype on citalopram disposition in 35 healthy
volunteers who received an oral dose of 20mg citalopram within a single-dose …

What is known and objective Genetic variations in drug‐metabolizing enzyme genes change
drug pharmacokinetics and response. CYP 2C19 is a clinically important enzyme that …

Objective Variations in cytochrome P450 (CYP) genes have been shown to be associated
with both accelerated and delayed pharmacokinetic clearance of many psychotropic …

Recently, a FDA Safety Communication warned of a dose-dependent risk for QTc
prolongation with citalopram, which is metabolized by CYP2C19 of the cytochrome P450 …

There is limited documentation of the importance of heterozygous cytochrome P450 (CYP)
mutations on drug exposure. This study was designed to evaluate the influence of …

Recently, a novel allelic variant of cytochrome P450 2C19 encoding ultrarapid enzyme
activity was described (denoted CYP2C19* 17). The objective of this study was to evaluate …

Background: Plasma concentrations of the S-enantiomer of citalopram were different
between extensive and poor CYP2C19 metabolizers in healthy subjects and depressed …